Highlights

• This patent demonstrates that Leonurine activates the PPARγ signaling pathway, significantly inhibiting inflammatory pathways and cytokine expression, thereby alleviating endothelial injury and inflammation caused by hyperlipidemia.
• Leonurine’s effects are dose-dependent, and it outperforms traditional drugs in certain parameters.
• Through a combination of animal studies and cellular models, the patent confirms Leonurine’s anti-inflammatory and vascular-protective mechanisms mediated by PPARγ, offering a new treatment approach for hyperlipidemia-related vascular disorders.

Summary

This invention patent investigates the mechanism and application of Leonurine in improving vascular inflammation associated with hyperlipidemia through the PPARγ signaling pathway.

Based on both animal and cell experiments, Leonurine was shown to activate PPARγ, which in turn regulates the downstream TNF-α–JNK–TLR4–NF-κB inflammatory pathway, thereby suppressing the abnormal expression of inflammatory cytokines such as IL-1β and IL-6. This leads to reduced vascular endothelial cell damage, inhibition of apoptosis, improvement in vascular tissue structure, and demonstrates anti-inflammatory and anti-atherosclerotic potential.

Experimental results revealed that Leonurine exhibits dose-dependent protective effects, with efficacy exceeding that of commonly used drugs such as aspirin and atorvastatin in certain indicators. This patent offers a novel therapeutic strategy for treating vascular inflammatory diseases associated with hyperlipidemia, and suggests that Leonurine or its extracts have potential for development as health supplements or pharmaceuticals.

朱依谆, 邱原野, “Application of Leonurine in Improving Vascular Inflammation under Hyperlipidemic Conditions via the PPAR Pathway,” China Patent CN114366733A, Apr. 19, 2022.